Company profile
OLEMA PHARMACEUTICALS, INC.
NASDAQ:OLMABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PALAZESTRANT | phase3 | — | 6 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04505826 | phase1_2 | completed | 2020-08-13 | 2024-07-30 | Olema Pharmaceuticals, Inc. | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer |
| NCT05266105 | phase1 | active_not_recruiting | 2021-12-10 | 2026-03-01 | Olema Pharmaceuticals, Inc. | A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients |
| NCT06016738 | phase3 | active_not_recruiting | 2023-11-16 | 2026-10-31 | Olema Pharmaceuticals, Inc. | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer |
| NCT07085767 | phase3 | recruiting | 2025-11-03 | 2028-12-01 | Olema Pharmaceuticals, Inc. | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer |
| NCT06784193 | phase1 | recruiting | 2024-12-16 | 2027-05-30 | Olema Pharmaceuticals, Inc. | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors |
FDA applications (0)
No records yet.